Search

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK

Four summer students -- Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner -- were named 2010 Rubin and Sarah Shaps Scholars.

… Thursday, September 1, 2011 Four summer students are named Rubin and Sarah Shaps Scholars each summer. Students are selected on the basis of their outstanding undergraduate credentials and their performance in our summer program. Jeannie Camarillo, a junior majoring in physiology at the University of

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

… Wednesday, August 30, 2017 Summary A novel form of immunotherapy called CAR T is now an FDA-approved option for people with acute lymphoblastic leukemia (ALL) that has stopped responding to chemotherapy. Our scientists played several key roles in CAR T cell therapy development. In what is being hailed

Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program. MSK physicians and scientists are involved in notable research to be presented at the meeting.

… Wednesday, May 27, 2020 Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program . The online meeting will provide an engaging lineup of scheduled and on-demand scientific content including a plenary session

The FDA has granted full approval to the targeted therapy selpercatinib (Retevmo®) for treating thyroid cancers that have certain changes in a gene called RET. Learn about MSK’s role in the development of this drug and about how patients may benefit.

… Wednesday, July 10, 2024 On June 12, 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy  selpercatinib (Retevmo ® ) for treating adult and pediatric patients 2 years and older with advanced or metastatic  thyroid cancers that have certain changes in a gene called

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

… Wednesday, January 10, 2024 Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to

Obtenga más información sobre el nuevo fármaco aprobado por la FDA, repotrectinib (AugtyroTM), que ataca las fusiones de ROS1 en el cáncer pulmonar y otros tipos de cáncer.

… Wednesday, January 10, 2024 Ingrid Adams, que ahora tiene 68 años, ha estado lidiando con el cáncer pulmonar metastásico durante más de una década. El tratamiento estándar, que incluye quimioterapia y radioterapia , mantuvo su enfermedad bajo control por un tiempo, pero el cáncer continuó diseminándose

Learn what can be done for patients like Stephanie Soto-Vega who confront financial hardships caused by cancer.

… Thursday, April 10, 2025 It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried

Meet a few of our brave and determined young patients who are thriving after receiving treatment at MSK.

… Friday, October 1, 2021 Ending cancer treatment is an exciting yet tricky transition for adolescents and young adults. But MSK keeps a close eye on these survivors as their physical, emotional, and social needs change over time. There are three survivorship clinics — each tailored to a specific age group